Needham Sees Major Upside in Atai Life Sciences' Depression Treatment
Needham initiates Atai Life Sciences with Buy rating and $12 target, projecting BPL-003 could capture 20% market share by 2035 with $2.5B+ in sales.
/ 1680 items
#XY↓
Barclays Initiates Bullish Coverage on Monopar Therapeutics
Barclays assigns Overweight rating to Monopar Therapeutics with $125 price target, highlighting de-risked biotech opportunities in inflammation, rare disease, and oncology sectors.
AstraZeneca Secures Tariff Relief by Pledging Deep Drug Discounts and $50 Billion U.S. Investment
AstraZeneca joins Pfizer in a landmark agreement with the Trump administration, promising "most-favored nation" drug prices, direct-to-consumer sales up to 80% off list price, and a massive investment in U.S. manufacturing in exchange for a three-year tariff exemption.
BofA Slashes Hims & Hers Q4 Forecast 6.5% Below Street
Bank of America maintains Underperform rating on Hims & Hers, slashing Q4 revenue forecast 6.5% below Street estimates to $590M, citing weak momentum and deferred revenue concerns.
The End of an Era: Optime Care Ceases Korlym Distribution Following Corcept’s Decision to End Exclusive Arrangement
The exclusive distributor for Corcept's drug Korlym quit after the company added a new pharmacy. This minor setback delays plans, but analysts advise buying the stock.
J&J Looks to Acquire Protagonist to Bolster Pipeline Amid Stelara Competition
Johnson & Johnson is reportedly discussing the purchase of Protagonist Therapeutics. This move could boost J&J's drug portfolio, especially in treatments for immune conditions and blood cancers.